Recent NEJM Study Exposing Patient Groups' Ties To Industry Sparks Calls For Transparency

A recent journal article finding a majority of the largest national patient advocacy groups have financial ties to industry has sparked debate on whether Congress or FDA should impose new transparency measures to ensure such groups' advocacy at agency advisory committee and public meetings is accurately represented. Multiple consumer advocates told Inside Health Policy they believe there should be mandatory disclosures of possible conflicts, particularly when these groups lobby FDA. But while some have floated the idea of banning...